TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

PURPOSE: Epidermal growth factor receptor (EGFR) is a targetable receptor frequently overexpressed in basal-like breast cancer, which comprises most triple-negative breast cancers (TNBCs), the only subtype without established targeted therapy. PATIENTS AND METHODS: In this randomized phase II trial,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Carey, Lisa A., Rugo, Hope S., Marcom, P. Kelly, Mayer, Erica L., Esteva, Francisco J., Ma, Cynthia X., Liu, Minetta C., Storniolo, Anna Maria, Rimawi, Mothaffar F., Forero-Torres, Andres, Wolff, Antonio C., Hobday, Timothy J., Ivanova, Anastasia, Chiu, Wing-Keung, Ferraro, Madlyn, Burrows, Emily, Bernard, Philip S., Hoadley, Katherine A., Perou, Charles M., Winer, Eric P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2012
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3413275/
https://ncbi.nlm.nih.gov/pubmed/22665533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.34.5579
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados